Mission Therapeutics and NeuraLight Partner to Bring Precision Brain Function Biomarkers to a Global Parkinson's Disease Clinical Trial
Spanning clinical sites across multiple countries including the UK, Europe and Australia, the partnership combines Mission's first-in-class, brain-penetrant USP30 inhibitor therapy to restore mitophagy with NeuraLight's precision biomarkers of brain function
Mission Therapeutics, a clinical-stage biotechnology company developing first-in-class therapeutics that enhance mitophagy to protect cell and organ health and NeuraLight, a leader in precision brain function measures, today announced a partnership to deploy NeuraLight's brain function biomarker assessments across Mission's multinational trial of MTX325 in Parkinson's disease.
MTX325 is a first-in-class, orally bioavailable and brain-penetrant USP30 inhibitor designed to restore mitophagy, the essential process by which cells clear dysfunctional mitochondria to maintain cellular health. Impaired mitophagy and mitochondrial dysfunction are central drivers of Parkinson’s disease pathology. By restoring this crucial clearing mechanism, MTX325 has the potential to protect vulnerable neurons. In preclinical studies published in Nature, USP30 inhibition was shown to protect against alpha-synuclein-induced loss of dopaminergic neurons.
